MBX BiosciencesMBX +3.77%12 PB Ratio is 5.67 as of Jun. 28, 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, MBX Biosciences ranks worse than 74.43% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-28), MBX Biosciences's share price is $52.21. MBX Biosciences's Book Value per Share for the quarter that ended in Mar. 2026 was $9.20. Hence, MBX Biosciences's PB Ratio of today is 5.67.
The historical rank and industry rank for MBX Biosciences's PB Ratio or its related term are showing as below:
MBX'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 5.67
Current: 5.67
During the past 4 years, MBX Biosciences's highest PB Ratio was 5.67. The lowest was 0.00. And the median was 0.00.
MBX's PB Ratio is ranked worse than 74.43% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs MBX: 5.67
During the past 12 months, MBX Biosciences's average Book Value Per Share Growth Rate was 6.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MBX Biosciences PB Ratio Related Terms
MBX Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for MBX Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MBX Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MBX Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MBX Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where MBX Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
MBX Biosciences's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
MBX Biosciences (MBX) has a PB Ratio of 5.67 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MBX Biosciences and its competitors. According to the industry distribution chart, MBX Biosciences ranks #917 out of 1232 companies in the Biotechnology industry, placing it in the top 74.4%.
Is MBX Biosciences' PB Ratio too high?
MBX Biosciences' current PB Ratio is 5.67. The Biotechnology industry median PB Ratio is 2.82. MBX Biosciences' value of 5.67 is 101.4% above this industry median. Based on the distribution chart, MBX Biosciences ranks #917 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' PB Ratio compare to ARDX and INBX?
According to the Biotechnology industry distribution chart, MBX Biosciences ranks #917 out of 1232 companies for PB Ratio. This places MBX Biosciences in the lower half of its industry. The industry median PB Ratio is 2.82. MBX Biosciences' value of 5.67 is 101.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MBX Biosciences's current PB Ratio of 5.67 is 101.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MBX Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MBX Biosciences's current PB Ratio is 5.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current PB Ratio of 5.67. The current PB Ratio is 5.67 and 101.4% above the Biotechnology industry median of 2.82. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For MBX Biosciences (MBX), the current PB Ratio is 5.67 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score
Get the complete analysis for MBX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBX has been successfully added to your 
